These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23365069)

  • 1. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis.
    Betts TR; Sadarmin PP; Tomlinson DR; Rajappan K; Wong KC; de Bono JP; Bashir Y
    Europace; 2013 Jun; 15(6):813-9. PubMed ID: 23365069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Right ventricular pacing is associated with impaired overall survival, but not with an increased incidence of ventricular tachyarrhythmias in routine cardioverter/defibrillator recipients with reservedly programmed pacing.
    Stockburger M; Celebi O; Krebs A; Knaus T; Nitardy A; Habedank D; Dietz R
    Europace; 2009 Jul; 11(7):924-30. PubMed ID: 19447808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to present treatment effects of implantable defibrillators? Statistics, baseline risk, and meaningful benefit.
    Theuns DA
    Europace; 2013 Jun; 15(6):777-8. PubMed ID: 23515339
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of slow ventricular tachycardia in heart failure patients with primary prophylactic implantable cardioverter defibrillator indication.
    Lüsebrink U; Duncker D; Hess M; Heinrichs I; Gardiwal A; Oswald H; König T; Klein G
    Europace; 2013 Jun; 15(6):820-6. PubMed ID: 23325044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early mortality in implantable cardioverter defibrillator patients: from randomized controlled trials to real life.
    Köbe J; Eckardt L
    Europace; 2009 Jun; 11(6):694-6. PubMed ID: 19470594
    [No Abstract]   [Full Text] [Related]  

  • 9. Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
    Silver MT; Sterns LD; Piccini JP; Joung B; Ching CK; Pickett RA; Rabinovich R; Liu S; Peterson BJ; Lexcen DR;
    Heart Rhythm; 2015 Mar; 12(3):545-553. PubMed ID: 25460168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator.
    Barsheshet A; Moss AJ; Huang DT; McNitt S; Zareba W; Goldenberg I
    J Am Coll Cardiol; 2012 Jun; 59(23):2075-9. PubMed ID: 22651863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.
    Proclemer A; Muser D; Campana A; Zoni-Berisso M; Zecchin M; Locatelli A; Brieda M; Gramegna L; Santarone M; Chiodi L; Mazzone P; Rebellato L; Facchin D
    Int J Cardiol; 2013 Sep; 168(2):1416-21. PubMed ID: 23287697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard 12-lead electrocardiography measures predictive of increased appropriate therapy in implantable cardioverter defibrillator recipients.
    Shi B; Harding SA; Jimenez A; Larsen PD
    Europace; 2013 Jun; 15(6):892-8. PubMed ID: 23118007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation.
    Chong D; Tan BY; Ho KL; Liew R; Teo WS; Ching CK
    Europace; 2013 Apr; 15(4):508-14. PubMed ID: 22848076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillators: do women fare worse than men? Gender comparison in the INTRINSIC RV trial.
    Russo AM; Day JD; Stolen K; Mullin CM; Doraiswamy V; Lerew DL; Olshansky B
    J Cardiovasc Electrophysiol; 2009 Sep; 20(9):973-8. PubMed ID: 19470037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death.
    Cuculich PS; Sánchez JM; Kerzner R; Greenberg SL; Sengupta J; Chen J; Faddis MN; Gleva MJ; Smith TW; Lindsay BD
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):207-13. PubMed ID: 17338717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial tachyarrhythmias in primary and secondary prevention ICD recipients: clinical and prognostic data.
    Botto GL; Luzi M; Ruffa F; Russo G; Ferrari G
    Pacing Clin Electrophysiol; 2006 Dec; 29 Suppl 2():S48-53. PubMed ID: 17169133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.
    Chen HA; Hsia HH; Vagelos R; Fowler M; Wang P; Al-Ahmad A
    Pacing Clin Electrophysiol; 2007 Mar; 30(3):390-4. PubMed ID: 17367359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.